Differentiation between Benign Prostatic Enlargement and Prostatic Cancer

DIFFEREN TIATION BETWEEN PROSTATIC\' C A RCINOMA A ND BENIGN PROSTATIC HYPERPLASIA BY AgNOR STAINING

Thirty cases of benign prostatic hyperplasia and 30 cases of prostatic adenocarcinoma were selected and stained by AgNOR (argyrophilic staining of the nucleolar organizer region) method. Specimens were obtained by either prostatectomy (open!TIJR) or needle biopsy of the prostate. In this study, the sections of prostatic adenocarcinoma were reviewed. 6 cases were diagnosed as well-differen...

Non – Detection of HPV DNA in Prostatic Cancer and Benign Prostatic Hyperplasia: a case- control study in Kerman

Background: Different studies assessed the role of inflammation in malignancy of different organs. Prostatitis has been suggested as a cause of cancer and BPH. Till now, more than 100 types of human Papilloma virus (HPV) are recognized including low and high-risk groups for carcinogenesis. Among them HPV-16 and HPV-18 have shown further association with cancer. Regarding the pr...

Prostatic Enlargement in Natives

Intraprostatic Botulinum Toxin injection in patients with benign prostatic enlargement

Histological evidence of benign prostatic hyperplasia (BPH) exceeded 50% in men over 50 years of age and rose to 75% as men entered the eighth decade. Therapeutic options for BPH generally fall into one of the three categories: watchful waiting, medical treatment and surgery. Excluding watchful waiting, the other forms of intervention directed at modifying the physiologic effects of BPH with or...

Urodynamic assessment in the laser treatment of benign prostatic enlargement.

OBJECTIVE To determine if bladder outlet obstruction can be adequately relieved after laser prostatectomy. PATIENTS AND METHODS Since November 1992, a total of 105 patients underwent laser treatment of the prostate because of complaints related to benign prostatic enlargement (BPE). To date, urodynamic data from a study of pressure flow analysis are available for 79 patients both at baseline ...